Common Stock
Equity Components [Axis]
Obligation to Issue Shares
Additional Paid-In Capital
Deficit Accumulated
Accumulated Other Comprehensive Income
Short Term Borrowing Total
Short-term Debt, Type [Axis]
Short term borrowing 1
Short term borrowing 2
Short term borrowing 3
Short Term Borrowing 4
Short Term Borrowing Total
Short Term Borrowing 5
Short Term Borrowing 2
Short Term Borrowing 3
Short Term Borrowing 4
Short Term Borrowing 5
Terms of Warrant
Class of Warrant or Right [Axis]
Terms of Warrant
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets
Cash
Inventory
Other current assets
Total current assets
Equipment
Total assets
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable
Accrued liabilities
Due to related parties
Notes and advances payable
Unearned revenue
Total liabilities
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 300,000,000 shares authorized; 40,244,605 and 31,000,000 shares issued and outstanding at November 30, 2016 and May 31, 2016, respectively
Additional paid-in capital
Obligation to issue shares
Accumulated deficit
Accumulated other comprehensive income
Total stockholders deficit
Total liabilities and stockholders deficit
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Income Statement [Abstract]
Revenue
Sales
Cost of goods sold
Gross margin
Operating expenses
Amortization
Consulting fees
General and administrative expenses
Research and development costs
Stock-based compensation
Total operating expenses
Other items
Accretion expense
Gain on sale of equipment
Interest
Loss on settlement of debt
Net loss
Unrealized foreign exchange translation gain
Comprehensive loss
Net loss per common share, basic and diluted
Weighted average number of shares outstanding, basic and diluted
Statement [Table]
Statement [Line Items]
Beginning balance, amount
Beginning balance, in shares
Shares issued for cash, amount
Shares issued for cash, shares
Shares issued for debt, amount
Shares issued for debt, shares
Issuance of shares subscribed, amount
Issuance of shares subscribed, shares
Stock-based compensation
Options issued for technology
Options issued for consulting fees
Warrants issued for term loan
Net loss for the period
Translation to reporting currency
Ending balance, amount
Ending balance, in shares
Statement of Cash Flows [Abstract]
Cash flows used in operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion expense
Accrued interest on notes payable
Amortization
Consulting fees - non-cash
Foreign exchange gain
Gain on sale of equipment
Loss on settlement of debt
Research and development costs - non-cash
Changes in operating assets and liabilities:
Inventory
Other current assets
Accounts payable
Accrued liabilities
Unearned revenue
Due to related parties
Net cash flows used in operating activities
Cash flows used in investing activities:
Acquisition of equipment
Net cash used in investing activities
Cash flows from financing activities:
Advances payable
Proceeds from notes payable
Proceeds from subscription to shares
Net cash provided by financing activities
Effects of foreign currency exchange on cash
Increase in cash
Cash, beginning
Cash, ending
Non-cash investing transactions:
Sale of equipment recorded as settlement of due to related parties
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Note 1 - Organization and Nature of Operations
Related Party Transactions [Abstract]
Note 2 - Related Party Transactions
Property, Plant and Equipment [Abstract]
Note 3 - Equipment
Inventory Disclosure [Abstract]
Note 4 - Inventory
Notes to Financial Statements
Note 5 - Unearned Revenue
Debt Disclosure [Abstract]
Note 6 - Notes and Advances Payable
Note 7 - Term Loan
Equity [Abstract]
Note 8- Share Capital
Subsequent Events [Abstract]
Note 9 - Subsequent Events
Schedule of Amounts Due To Related Parties
Schedule of Related Party Transactions
Amortization schedule, equipment
Schedule of short term loans and advances, November 30, 2016
Schedule of short term loans and advances, May 31, 2016
Assumptions, Fair value of warrants
Schedule of Fair Value of Options Granted and Assumptions August 26, 2015
Schedule of Fair Value of Options Granted and Assumptions January 13, 2015
Schedule of Fair Value of Options Granted and Assumptions August 5, 2015
Schedule of Changes in Stock Options
Schedule of Outstanding Options
Schedule of Warrant expiration dates, March 3, 2016 issuance
Schedule of Warrant expiration dates, October 12, 2016 issuance
Schedule of changes in Warrants
Schedule of Warrants outstanding
Due to the Chief Executive Officer (CEO) and President
Due to the Vice President (VP), Corporate Strategy
Due to the VP, Technology and Operations
Due to the Chief Medical Officer
Due to a company owned by VP, Corporate Strategy and VP Technology and Operations
Due to the Chief Financial Officer (CFO)
Due to related parties
Management fees incurred to the CEO and President
Stock-based compensation incurred to the CEO and President (Note 8)
Management fees incurred to the CFO
Consulting fees incurred to the VP, Corporate Strategy
Consulting fees incurred to the VP, Technology and Operations
Net payments received for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy
Value of options issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8)
Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs
Stock-based compensation incurred to the Chief Medical Officer (Note 8)
Research and development costs incurred to a company controlled by the Chief Medical Officer
Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6)
Accretion expense associated with a term loan entered into with significant shareholder (Note 7)
Total transactions with related parties
Transactions with Jean Arnett and Brad Hargreaves
Monthly consulting fee, Canadian Dollars
Term of renegotiated consulting fee commencing August 1, 2016, in months
Book value, beginning of the period
Changes during the period
Amortization
Book value, end of the period
Inventory, supplies for resale
Deposit received
Deposit received (CDN dollar equivalent)
Principal Outstanding
Interest Rate per Annum
Additional Description
Accrued Interest
Total
As at May 31, 2016
Notes and advances
Loans, unrelated parties
Interest rate
Loans, Richard Jeffs, major shareholder, total (USD)
Loans, Richard Jeffs, major shareholder, total (CAD)
Loans, Richard Jeffs, due on demand, (CAD)
Interest rate
Interest expense
Transactions with Richard Jeffs
Amount of assignment of debt to third parties
Non-brokered Private Placement Offering and debt settlement
Price Per Unit
Units Issued to Holders of Notes payable
Debt Settlement proceeds
Principal converted to shares
Accrued interest converted to shares
Terms of Units
Exercise Price, Share purchase warrants
Loss on debt settlement
Fair market value of common stock on date of debt conversion
Assumptions used in warrant valuation
Expected Warrant Life
Risk-Free Interest Rate
Expected Dividend Yield
Expected Stock Price Volatility
Loan agreement - March 3, 2016
Loan proceeds
Interest rate
Share purchase warrants issued as consideration
Term of warrants, years
Exercise price, warrants
Effective interest rate
Accretion Expense
Option Valuation Assumptions
Expected Life of Options
Risk-Free Interest Rate
Expected Dividend Yield
Expected Stock Price Volatility
Expected Life of Options
Risk-Free Interest Rate
Expected Dividend Yield
Expected Stock Price Volatility
Expected Life of Options
Risk-Free Interest Rate
Expected Dividend Yield
Expected Stock Price Volatility
Stock Option Activity
Options outstanding, beginning
Options granted
Options cancelled
Options outstanding, ending
Options exercisable, ending
Weighted Average Exercise Price
Options outstanding, beginning
Options granted
Options cancelled
Options outstanding, ending
Options exercisable, ending
Details of Options Outstanding
Exercise Price
Number of Options Granted
Number of Options Exercisable
Total Options granted
Exercise price, warrants
Warrant Activity
Warrants outstanding, beginning
Warrants issued
Warrants outstanding, ending
Details of Warrants Oustanding
Exercise Price
Number of warrants exerciseable
Warrant expiry date
Transactions during January 2015
Subscription units
Price per Unit
Proceeds from subscription
Terms of Units
Units Issued
Total Proceeds
Options Issued - November 25, 2014
Stock option issued
Exercise Price per Share
Options Vested
Total Fair Value Option Vested
Unvested stock options canceled
Options Issued - January 13, 2015 - CMO
Stock Option Issued
Exercise Price per Share
Share which vest each quarter
Total fair value options granted
Options Vested at report date
Stock based compensation expense recognized in period
Stock based compensation expense recognized in future periods
Options Issued August 5, 2015 - CEO
Stock Option Issued
Exercise Price per Share
Total fair value options granted
Stock based compensation expense recognized in period
Weighted average remaining contractual life, oustanding stock options at report date
Warrants
Share purchase warrants granted
Remaining contractual life
Number of eBalance Pro wellness devices received
Payment to developer for devices
Payment to developer for devices, EUROS
Proceeds from Loan Agreements, CAD, unrelated party
Proceeds from Loan Agreement, CAD, Jeffs
Interest rate on loans
Consulting fees incurred, Vice President Corporate Strategy
Consulting fees incurred, Vice President Technology and Operations
Due to CEO
Amounts due and payable to CFO
Due to Chief Medical Officer
Amounts due and payable to Company owned by VP Corporate Strategy and VP Technology
Due to Vice President Corporate Strategy
Due to Vice President Technology and Operations
Equipment acquired from VP Technology and VP Corporate Strategy, amount
The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period.
Management fees incurred, CEO and President
Management fees incurred, CFO
Obligation to issue shares,
Obligation to Issue Shares, Member
Property, Plant and Equipment, Amortization, Table Text Block
Research and development charges incurred by Chief Medical Officer
Granted Stock Options, weighted average exercise price
Stock options, grants in period
Short Term Debt
Short Term Debt
Short Term Debt, Total, Member
Stock-based compensation incurred, Chief Medical Officer
Total Short Term Debt, including Interest
Total Transactions, related parties
Unrealized foreign currency exchange gain
Share based compensation, Options issued, value
Share based compensation, options issued to consultants
Short Term Debt, Short term Borrowings
Short Term Debt, Short term Borrowings
Short Term Debt, Short term Borrowings
Short Term Debt, Short term Borrowings
Short Term Debt, Short term Borrowings, TOTAL
Share purchase warrants issued as consideration
Term of share purchase warrants in years
Share based compensation, stock options, valuation assumptions
Share based compensation, stock options, valuation assumptions
Share based compensation, fair value assumption, risk free interest rate, options granted
Share based compensation, fair value assumption, expected volatiliy, options granted
Share based compensation, expected dividend rate, options granted
Share based compensation, fair value assumption, expected term, options granted
Share based compensation, fair value assumption, risk free interest rate, options granted
Share based compensation, fair value assumption, expected volatiliy, options granted
Share based compensation, expected dividend rate, options granted
Share based compensation, fair value assumption, expected term, options granted
Share based compensation, fair value assumption, risk free interest rate, options granted
Share based compensation, fair value assumption, expected volatiliy, options granted
Share based compensation, expected dividend rate, options granted
Number of shares vesting each quarter under stock option plan, Consultant
Additions (reductions) to property and equipment
ShortTermDebtTotalMember
ShortTermDebt9Member
ShortTermDebt10Member
WarrantMember2Member
Assets, Current
Assets
Liabilities, Current
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Gross Profit
Costs and Expenses
Interest Expense
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Common Stock, Shares, Outstanding
Stock Granted, Value, Share-based Compensation, Gross
Amortization [Default Label]
GainOnSaleOfEquipmentCF
GainsLossesOnExtinguishmentOfDebtCF
Increase (Decrease) in Inventories
Increase (Decrease) in Other Current Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Recognition of Deferred Revenue
Increase (Decrease) in Due to Related Parties
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Net Cash Provided by (Used in) Financing Activities
Cash, Period Increase (Decrease)
Cash Equivalents, at Carrying Value
Cash and Cash Equivalents, at Carrying Value
TotalTransactionsRelatedParties
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
DebtInstrumentInterestRateEffectivePercentage2
Debt Instrument, Interest Rate During Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1a
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1a2
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate2
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate2
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm3
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1a3
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate3
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ExercisePricesWarrants
TermsOfSubscriptionUnits
ExercisePriceStockOptionJan2015
StockOptionIssuedAugust2015
ExercisePriceStockOptionAugust2015
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValueCEO
ShareBasedCompensationInPeriodAug2015Option
ShortTermDebt6Member